<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01564329</url>
  </required_header>
  <id_info>
    <org_study_id>sim-endo-201201</org_study_id>
    <nct_id>NCT01564329</nct_id>
  </id_info>
  <brief_title>The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar</brief_title>
  <official_title>The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Simcere Pharmaceutical Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Simcere Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the change of blood perfusion before/after the use of Endostar, discuss the time
      sequence of Endostar TM in treating advanced lung adenocarcinoma in normalization window
      period.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change of blood perfusion before/after the use of Endostar</measure>
    <time_frame>per 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumor to progress</measure>
    <time_frame>6 months</time_frame>
    <description>tumor to progress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical benefit rate</measure>
    <time_frame>per 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Reaction</measure>
    <time_frame>per 1 day</time_frame>
    <description>NCI-CTCAE V3.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Advanced Primary Lung Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>endostar2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT Perfusion Imaging(CTPI) at D0, D21 of the first cycle、D6, D14 of the second cycle, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>endostar1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT Perfusion Imaging(CTPI) at D0，D6, D14, D21 of the first period, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>endostar</intervention_name>
    <description>Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.</description>
    <arm_group_label>endostar2</arm_group_label>
    <arm_group_label>endostar1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically newly diagnosed as unresectable and metastasis
             advanced lung adenocarcinoma(Stage IV, Seventh Edition of the UICC/AJCC Classification
             for Lung Cancer).

          -  At least one measurable objective tumor lesion, spiral CT or PET-CT examination: the
             shortest diameter ≥2cm，and no obvious necrosis

          -  Life expectancy ≥12weeks

          -  Patients receive palliative radiotherapy for bone's pain relief; patients receive
             radiotherapy for brain metastasis、patients after brain transfer operation or radiation
             therapy are allowed to enter the research.

          -  18≤Patients'age ＜70 years.

          -  Electrocolonogram (ECOG) Score:0-1.

          -  Granulocyte count ≥ 2.0×109/L, platelet count ≥ 100×109/L.

          -  Serum bilirubin within the normal range.

          -  Aspartate aminotransferase ( AST ), Alanine aminotransferase ( ALT ) within the normal
             range(if the patients is diagonosed as liver metastasis,his/her AST/ALT should not
             surpass 1.5 times of the normal range ).

          -  Serum creatinine within the normal range and creatinine clearance rate ≥60ml/min

          -  Compliance with research requirements and be able to follow up.

          -  Within 72 hours before the treatment, all women pregnant with pregnant possibility
             should undergo pregnancy test and get negative results.

          -  Patients with fertility ability should take effective contraceptive techniques.

          -  Sign informed consent of this clinic trial.

        Exclusion Criteria:

          -  Lung adenocarcinoma patients who received systemic chemotherapy/thoracic
             radiotherapy/targeted therapy

          -  Received resection, cutting or aspiration within seven days

          -  Any unstable systemic diseases (including peptic ulcer、active infection、grade4
             hypertension、unstable angina、congestive heart failure、liver, metabolic disorders or
             fracture、unhealing wound )

          -  Chronic kidney disease history(including chronic nephritis, nephrotic syndrome,
             Obstruction of urinary tract etc. caused by Urinary calculus)

          -  have to use anticoagulant drugs at the same time

          -  patients with obvious coagulation disorders、active bleeding and bleeding tendency

          -  Any other malignancies (complete cure of cervical carcinoma in situ/basal cell
             carcinoma/squamous cell carcinoma are excluded )happened within 5 years.

          -  Signifinant weight loss, weight lost during the 6 weeks more than or equal to 10%

          -  Patients who take bone metastasis as the only observing index

          -  Allergic to escherichia coli preparation

          -  Used Endostar before

          -  Lactating women

          -  Contraindications written on Pemetrexed、Carboplatin、Dexamethasone instructions

          -  Allergic to radiographic contrast agents

          -  In the middle or planning to attend other clinic trails
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>You Lu, MD</last_name>
    <phone>86-028-85422114</phone>
    <email>radyoulu@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meijuan Huang, MD</last_name>
    <phone>86-028-85422114</phone>
    <email>hmj107@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Department of Thoracic Oncology in West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meijuan Huang, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>You Lu, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2012</study_first_posted>
  <last_update_submitted>March 23, 2012</last_update_submitted>
  <last_update_submitted_qc>March 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endostar</keyword>
  <keyword>CT Perfusion</keyword>
  <keyword>Advanced Primary Lung Adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

